Iterum Therapeutics plc Ordinary Share (ITRM)

Price$0.06

Value ScoreB

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-97.03%

Price vs S&P 500 (4W)-8.90%

VGM Score33.03

Market Capitalization$746,082

All Metrics

Book Value / Share (Quarterly)$0.26

P/TBV (Annual)0.39x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.39

Price vs S&P 500 (YTD)-93.20%

Net Profit Margin (TTM)-2302.31%

EPS (TTM)$-0.75

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-0.75

EPS (Annual)$-1.25

ROI (Annual)-78.68%

Net Profit Margin (5Y Avg)-40639.07%

Cash / Share (Quarterly)$0.22

ROA (Last FY)-55.56%

EBITD / Share (TTM)$-0.55

ROE (5Y Avg)-116.44%

Operating Margin (TTM)-1982.31%

Cash Flow / Share (Annual)$-0.84

P/B Ratio0.22x

P/B Ratio (Quarterly)2.92x

Net Income / Employee (Annual)$-2,777,800

EV / Revenue (TTM)60.20x

Net Interest Coverage (TTM)-0.37x

ROA (TTM)-74.63%

EPS Incl Extra (Annual)$-1.25

Current Ratio (Annual)1.39x

Quick Ratio (Quarterly)1.80x

3-Month Avg Trading Volume11.32M

52-Week Price Return-94.73%

Revenue / Employee (TTM)$43,300

Tangible BV / Share (Quarterly)$0.23

P/S Ratio (Annual)18.65x

Asset Turnover (Annual)0.00x

52-Week High$1.28

Operating Margin (5Y Avg)-31510.38%

EPS Excl Extra (Annual)$-1.25

CapEx CAGR (5Y)-36.90%

Tangible BV CAGR (5Y)-7.85%

26-Week Price Return-89.11%

Quick Ratio (Annual)1.36x

13-Week Price Return-70.05%

Total Debt / Equity (Annual)1.02x

Current Ratio (Quarterly)2.13x

Enterprise Value$23.48M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-45.24%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-256725.00%

Cash / Share (Annual)$0.75

3-Month Return Std Dev685.38%

Net Income / Employee (TTM)$-2,995,400

ROE (Last FY)-158.68%

Net Interest Coverage (Annual)-3.44x

EPS Basic Excl Extra (Annual)$-1.25

Total Debt / Equity (Quarterly)5.76x

EPS Incl Extra (TTM)$-0.75

ROI (TTM)-74.22%

P/S Ratio (TTM)1.91x

Pretax Margin (5Y Avg)-40344.92%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.09

Price vs S&P 500 (52W)-119.09%

Year-to-Date Return-85.04%

5-Day Price Return-26.65%

EPS Normalized (Annual)$-1.25

ROA (5Y Avg)-105.37%

Net Profit Margin (Annual)-257825.00%

Month-to-Date Return-36.58%

Cash Flow / Share (TTM)$-2.30

EBITD / Share (Annual)$-1.25

Operating Margin (Annual)-255050.00%

LT Debt / Equity (Annual)1.02x

ROI (5Y Avg)-84.30%

LT Debt / Equity (Quarterly)5.76x

EPS Basic Excl Extra (TTM)$-0.75

P/TBV (Quarterly)3.30x

P/B Ratio (Annual)0.37x

Pretax Margin (TTM)-2268.46%

Book Value / Share (Annual)$2.22

Price vs S&P 500 (13W)-78.31%

Beta3.91x

Revenue / Share (TTM)$0.01

ROE (TTM)-216.35%

52-Week Low$0.01

vGradeB

mGradeF

vgmGradeD

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

2.17

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ITRMIterum Therapeutics plc Ordinary Share	B	—	F	$0.06
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Iterum Therapeutics is a pharmaceutical company commercializing Orlynvah, an oral-branded penem antibiotic approved in the United States for treating complicated urinary tract infections. Orlynvah has the potential to be the first and only oral and intravenous branded penem available globally. The company targets drug-resistant bacterial infections, addressing a significant unmet medical need.